Combogesic (acetaminophen/ibuprofen): Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See NDA 215320's history or AFT Pharmaceuticals's company page.
On Jun 30, 2022, FDA declined to approve Combogesic (acetaminophen/ibuprofen) (NDA 215320) from AFT Pharmaceuticals Ltd. in its present form, citing nonclinical. The application was later approved.
- Letter date: Jun 30, 2022
- Application: NDA 215320
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDAYou have not provided adequate toxicological risk assessments for leachables over the 5 mcg/day qualification threshold. We acknowledge your original approach in utilizing a ‘oxicological threshold of concern of 120 mcg/day as recommended in ICH M7. However, t...… openFDA did not return the full text just now. Open it in the letter search.
AFT Pharmaceuticals's Other Letters
Newest first- SirolimusJan 25, 2024 · NDA 218528 · not approved
- Combogesic (acetaminophen and ibuprofen)Nov 6, 2020 · NDA 209471 · later approved
- NDA 209471Dec 22, 2017 · NDA 209471 · later approved
Record
- Company
- AFT Pharmaceuticals Ltd.
- Application
- NDA 215320
- Status in openFDA
- Approved
- Review division
- Office of Neuroscience
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters